In the article “Pharmacology, Part 3A: Interventional Medications in Renal and Biliary Imaging” by Currie (J Nucl Med Technol. 2018;46:326–334), information from an additional guideline was inadvertently left out of the “Sincalide (Kinevac; Bracco Diagnostics Inc.)” section. The corrected paragraph and additional reference appear below. The author regrets the error.
Proper Use and Dose Administration. The patient should have fasted for a minimum of 4 h and a maximum of 6 h to ensure that gallbladder filling of the radiopharmaceutical is not impeded by residual endogenous cholecystokinin (45-min half-life) contracting the gallbladder or a full gallbladder due to absence of any endogenous cholecystokinin for a long period (1). The traditional dose of sincalide is 0.02 μg/kg intravenously over 3–5 min (1,12,15,17,18). A larger second dose of 0.04 μg/kg diluted in 10 mL of saline administered intravenously over 5 min may be used if gallbladder contraction is not achieved with the first dose (1,12). The short duration administration produces greater variability in the normal gall bladder ejection fraction, and the current SNMMI guideline advises a 30–60 min infusion of 0.02 μg/kg or over 3 min for sphincter of Oddi dysfunction. More recent studies by Ziessman et al. recommend the use of an infusion 0.02 μg/kg over 60 min to reduce variability in response.
Additional reference:
Ziessman H, Tulchinsky M, Lavely W, et al. Sincalide-stimulated cholescintigraphy: A multicentre investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. J Nucl Med. 2010:51:277–281.
